Sandoz Announces Further Progress in its Biosimilars Portfolio, with the Publication of Positive Results from the Integrated Phase I/III Clinical Trial of Denosumab

Sandoz Announces Further Progress in its Biosimilars Portfolio, with the Publication of Positive Results from the Integrated Phase I/III Clinical Trial of Denosumab

The ROSALIA study met the primary endpoints, confirming that the proposed biosimilar denosumab matches the reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in postmenopausal women with osteoporosis Osteoporosis is responsible for 8.9 million bone fractures a year, including debilitating hip fractures – a number that is expected to rise dramatically over …

Sandoz Announces Further Progress in its Biosimilars Portfolio, with the Publication of Positive Results from the Integrated Phase I/III Clinical Trial of Denosumab Read More »